Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Cash & Equivalents (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Cash & Equivalents for 3 consecutive years, with $164.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 359.33% to $164.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $164.1 million through Dec 2025, up 359.33% year-over-year, with the annual reading at $164.1 million for FY2025, 359.33% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $164.1 million at Nuvation Bio, up from $98.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $248.0 million in Q2 2025, with the low at $24.4 million in Q3 2023.
  • Average Cash & Equivalents over 3 years is $70.1 million, with a median of $39.2 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents crashed 31.52% in 2024, then surged 623.26% in 2025.
  • Over 3 years, Cash & Equivalents stood at $42.6 million in 2023, then fell by 16.24% to $35.7 million in 2024, then skyrocketed by 359.33% to $164.1 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $164.1 million, $98.9 million, and $248.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.